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Gabapentin for chronic pelvic pain in women (GaPP2): 
a multicentre, randomised, double-blind, placebo-controlled 
trial
Andrew W Horne, Katy Vincent, Catherine A Hewitt, Lee J Middleton, Magda Koscielniak, Wojciech Szubert, Ann M Doust, Jane P Daniels, on behalf 
of the GaPP2 collaborative
Summary
Background Chronic pelvic pain affects 2–24% of women worldwide and evidence for medical treatments is scarce. 
Gabapentin is effective in treating some chronic pain conditions. We aimed to measure the efficacy and safety of 
gabapentin in women with chronic pelvic pain and no obvious pelvic pathology.
Methods We performed a multicentre, randomised, double-blind, placebo-controlled randomised trial in 39 UK 
hospital centres. Eligible participants were women with chronic pelvic pain (with or without dysmenorrhoea or 
dyspareunia) of at least 3 months duration. Inclusion criteria were 18–50 years of age, use or willingness to use 
contraception to avoid pregnancy, and no obvious pelvic pathology at laparoscopy, which must have taken place at 
least 2 weeks before consent but less than 36 months previously. Participants were randomly assigned in a 1:1 ratio to 
receive gabapentin (titrated to a maximum dose of 2700 mg daily) or matching placebo for 16 weeks. The online 
randomisation system minimised allocations by presence or absence of dysmenorrhoea, psychological distress, 
current use of hormonal contraceptives, and hospital centre. The appearance, route, and administration of the 
assigned intervention were identical in both groups. Patients, clinicians, and research staff were unaware of the trial 
group assignments throughout the trial. Participants were unmasked once they had provided all outcome data at 
week 16–17, or sooner if a serious adverse event requiring knowledge of the study drug occurred. The dual primary 
outcome measures were worst and average pain scores assessed separately on a numerical rating scale in weeks 13–16 
after randomisation, in the intention-to-treat population. Self-reported adverse events were assessed according to 
intention-to-treat principles. This trial is registered with the ISRCTN registry, ISCRTN77451762.
Findings Participants were screened between Nov 30, 2015, and March 6, 2019, and 306 were randomly assigned (153 to 
gabapentin and 153 to placebo). There were no significant between-group differences in both worst and average numerical 
rating scale (NRS) pain scores at 13–16 weeks after randomisation. The mean worst NRS pain score was 7·1 (standard 
deviation [SD] 2·6) in the gabapentin group and 7·4 (SD 2·2) in the placebo group. Mean change from baseline was –1·4 
(SD 2·3) in the gabapentin group and –1·2 (SD 2·1) in the placebo group (adjusted mean difference –0·20 [97·5% CI 
–0·81 to 0·42]; p=0·47). The mean average NRS pain score was 4·3 (SD 2·3) in the gabapentin group and 4·5 (SD 2·2) 
in the placebo group. Mean change from baseline was –1·1 (SD 2·0) in the gabapentin group and –0·9 (SD 1·8) in the 
placebo group (adjusted mean difference –0·18 [97·5% CI –0·71 to 0·35]; p=0·45). More women had a serious adverse 
event in the gabapentin group than in the placebo group (10 [7%] of 153 in the gabapentin group compared with 
3 [2%] of 153 in the placebo group; p=0·04). Dizziness, drowsiness, and visual disturbances were more common in 
the gabapentin group.
Interpretation This study was adequately powered, but treatment with gabapentin did not result in significantly lower 
pain scores in women with chronic pelvic pain, and was associated with higher rates of side-effects than placebo. 
Given the increasing reports of abuse and evidence of potential harms associated with gabapentin use, it is important 
that clinicians consider alternative treatment options to off-label gabapentin for the management of chronic pelvic 
pain and no obvious pelvic pathology.
Funding National Institute for Health Research.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Chronic pelvic pain is estimated to affect 2–24% of 
women worldwide, and is associated with substantially 
reduced quality of life and a 45% reduction in work 
productivity.1–3 It can be associated with underlying 
pathology such as endometriosis, but in up to 55% of 
women, no obvious cause is identified at laparoscopy.3 
Management of chronic pelvic pain within gynaecological 
practice is difficult as no established treatments are 
available, but careful exploration of symptoms and 
history can point to non-gynaecological causes of chronic 
pelvic pain, for which some effective treatments exist.4
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The off-label use of gabapentin for chronic pelvic pain 
has increased because of its proven efficacy in other 
chronic pain conditions.5,6 Gabapentin primarily affects 
modulation of pain by the CNS, and neuroimaging 
studies have shown gabapentinoids affect brain function 
in models of central sensitisation and in patients with 
chronic pain.7,8 There is also some evidence for peripheral 
activity.
Data from randomised clinical trials of the use of 
gabapentin in women with chronic pelvic pain are scarce. 
One trial compared the efficacy of gabapentin and 
amitriptyline for chronic pelvic pain in women with a 
range of pelvic pathologies9 but this study was open-label, 
there was no placebo group, the population had a mixed 
aetiology of pain symptoms, and the numbers analysed 
were small with only 56 participants in total. GaPP1, our 
own pilot trial of gabapentin, was not powered to detect 
meaningful differences between gabapentin and placebo 
for chronic pelvic pain.10 Another randomised, placebo-
controlled trial of 60 women did show a (statistically, and 
potentially clinically) significant difference in patient-
reported pain after 12 weeks of treatment but the 
variability of patient responses was considerably lower 
than all previous studies in chronic pelvic pain, and not 
generalisable outside of that population.11 In this study, 
we aimed to establish the efficacy and safety of gabapentin 
in women with chronic pelvic pain and no obvious pelvic 
pathology.
Methods
Study design and participants
This multicentre, randomised, double-blind, placebo-
controlled trial (GaPP2) took place in 39 UK hospital 
centres. Ethical approval for the trial was obtained from 
Research in context
Evidence before this study
At the time of the design of the pilot study for this trial (GaPP1), 
there had been an increase in prescription of gabapentin in 
general within the UK. The rate of patients newly treated with 
gabapentinoids in primary care tripled from 2007 to 2017, 
and by 2017 half of the prescriptions of gabapentinoids were 
for an off-label indication. At the time, we also observed that 
there was considerable use of gabapentin for chronic pelvic pain 
(largely because of its perceived effectiveness in other chronic 
pain conditions). First, we surveyed a random group of general 
practitioners, with the support of the Scottish Primary Care 
Research Network. Of the general practitioners who responded 
to our survey, 74% said that they would consider gabapentin as 
a treatment option for chronic pelvic pain in women. Second, 
we surveyed a random group of gynaecologists, with the 
support of the Royal College of Obstetricians and 
Gynaecologists. Of those who responded to our survey, 
50% said that they currently prescribe gabapentin for chronic 
pelvic pain, and 92% said that they would consider gabapentin 
as a treatment option for this condition. Since then, awareness 
and use of gabapentinoids has continued to increase in 
gynaecology, with the publication of reviews in this area and 
reference within the National Institute for Health and Care 
Excellence (NICE) guideline for endometriosis to the NICE 
guideline on neuropathic pain for treatment of chronic pelvic 
pain with neuromodulators. However, data from randomised 
clinical trials of the use of gabapentin in women with chronic 
pelvic pain are scarce. A 2017 Cochrane review identified one 
trial that compared the efficacy of gabapentin and amitriptyline 
for chronic pelvic pain in women with a range of pelvic 
pathologies, but this study was open-label, there was no 
placebo group, the population had a mixed aetiology of pain 
symptoms, and the numbers analysed were small, with only 
56 participants. An update to the Cochrane review search 
strategy in MEDLINE, Embase, PsychLit, and CAB abstracts to 
April 15, 2020, found only our own pilot trial (GaPP1) and one 
other placebo-controlled trial from Egypt, neither of which 
were powered to detect significant differences, and both had 
substantial attrition. An increased risk of suicidal behaviour, as a 
potential side-effect of gabapentin, and possible misuse of the 
drug have been of concern with the rise in the prescribing of 
gabapentin.
Added value of this study
This study is the first large, randomised, placebo-controlled 
clinical trial to report on treatment of chronic pelvic pain with 
gabapentin. Although it conflicts with the results of the 
Egyptian trial, the robustness of the study design, including 
masking to treatment allocation of both participants and 
investigators, ensured internal validity, enabling the results to 
be interpreted with confidence. Groups were balanced with 
respect to dysmenorrhoea, psychological distress, and 
concomitant use of hormonal contraceptives—all potentially 
prognostic for reported pain. The design of our trial reflects the 
real-word choices that women and their gynaecologists make 
about the management of chronic pelvic pain. We can 
confidently conclude that gabapentin is not effective for 
chronic pelvic pain in women.
Implications of all the available evidence
Women with chronic pelvic pain and no obvious pelvic 
pathology should be advised that gabapentin might not 
alleviate their pain and could give them unpleasant side-effects. 
In our opinion, no further research is required to establish the 
role of gabapentin in the management of chronic pelvic pain in 
women with no obvious pelvic pathology. Questions that 
remain unaddressed relate to the use of other pharmacological 
interventions (monotherapy vs combination therapy), 
physiotherapy, and cognitive behavioural therapy for treating 
chronic pelvic pain in women. It is possible that subgroups of 
women could benefit from gabapentin, but these will need to 
be carefully characterised and explored.
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the UK Coventry and Warwick Research Ethics Committee 
(REC 15/WM/0036) and clinical trial authorisation was 
obtained from the Medicines and Healthcare Products 
Regulatory Authority. A trial steering committee provided 
independent oversight of the trial. Confidential interim 
analysis of all available data alongside anonymised reports 
of adverse events by participants were reviewed by a data 
monitoring committee on four occasions. No reason to 
recommend halting or modifying the trial was identified. 
The trial protocol has been published elsewhere.12
The recruitment criteria for this study were defined 
before the International Classification of Diseases-11 
classification for chronic secondary visceral pain was 
drawn up, and were based on the Royal College of 
Obstetricians and Gynaecologists definition for chronic 
pelvic pain and the 2012 International Association for the 
Study of Pain taxonomy.13,14 Moreover, we believe that 
they reflect the group of women commonly seen in 
gynaecological practice within the UK and that any 
heterogeneity is a strength, ensuring that our results are 
generalisable. Eligible participants were women with 
chronic pelvic pain (with or without dysmenorrhoea or 
dyspareunia) of at least 3 months duration. We limited 
the study to women because of the growing body of 
evidence from preclinical and clinical studies that 
suggest sex differences in pain thresholds, sensitivity, 
and underlying neuroimmune modulation.15,16 Pelvic 
pain was defined as pain located within the true pelvis 
(between and below the anterior iliac crests). Inclusion 
criteria were 18–50 years of age, use or willingness to use 
Figure 1: Trial profile
The final worst pain score was taken as the worst response from the worst pain scores returned, and the average pain score as the mean of the average pain scores 
returned. Adherence to treatment was defined as taking more than 50% of the study drug, self-reported at weeks 16–17. Participants were withdrawn from any 
further follow-up if they withdrew consent. NRS=numerical rating scale.
153 assigned to gabapentin
101 adherent 
  32 insufficient adherence data
  11 non-adherent
8 withdrew consent
1 died (unrelated) 
123 data available for analysis of 
primary outcome for average 
pain scores
30 missing data imputed
121 data available for analysis of 
primary outcome for average 
pain scores
32 missing data imputed
124 data available for analysis of 
primary outcome for worst pain 
scores
29 missing data imputed
122 data available for analysis of 
primary outcome for worst pain 
scores
31 missing data imputed
153 assigned to placebo 
101 adherent 
 42 insufficient adherence data
 8 non-adherent
2 withdrew consent
394 returned  ≥3 NRS pain scores
(both pain scales)
306 randomised 
76 did not return for randomisation
12 did not report at least two worst pain scores ≥4
414 participated in run-in phase  
20 returned <3 NRS pain scores
1348 participants assessed for eligibility 
934 ineligible
 486 not interested
 261 uncontactable following approach
 85 no reason 
 28 no longer in pain following laparoscopy
 16 other
 15 were pregnant or wanted to conceive
 14 current or previous gabapentin use 
 17 contraindications to gabapentin
 4 cyclical pain 
 4 had laparoscopy >3 years ago
 2 wanted to try other treatments 
 1 did not reach Rome III Diagnostic Criteria 
 1 previously participated in GaPP pilot 
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contraception to avoid pregnancy, and no obvious pelvic 
pathology at laparoscopy (eg, macroscopic endometriosis 
lesions, complex ovarian cysts or ovarian cysts of >5 cm, 
fibroids of >3 cm, and dense adhesions), which must 
have taken place at least 2 weeks before consent but less 
than 36 months previously. Women were excluded if 
they only had dysmenorrhoea; had a malignancy; were 
currently using or had previously used gabapentin or 
pregabalin; had surgery planned in next 6 months; had 
contraindications to taking gabapentin; had a previous 
reaction to gabapentin; were taking gonadotrophin-
releasing hormone agonists and were unable or unwilling 
to stop; were breastfeeding, pregnant, or planned a 
pregnancy in next 6 months; or had pain suspected to be 
of gastrointestinal origin (according to positive Rome III 
Diagnostic Criteria); or had previously participated in the 
GaPP1 pilot study. All women provided written informed 
consent. After confirmation of clinical eligibility, women 
entered a pre-randomisation screening phase where 
they were required to return their worst and average 
pain scores on a numerical rating scale (NRS) ranging 
from 0 (no pain) to 10 (worst pain imaginable), weekly 
for 4 weeks via a centralised text messaging system. To 
be considered eligible for randomisation, women were 
required to have returned at least three of four pre-
randomisation NRS scores on both the worst and average 
NRS scales to show adherence to data collection. At least 
two of the worst NRS pain scores needed to be a score 
of 4 or higher, for the pain to be considered sufficient for 
entry into the trial. No study drugs were taken during 
this pre-randomisation screening phase, but participants 
were able to remain on any analgesics they were taking. 
We did not specify a target recruitment per centre; all 
centres recruited as many women as they could during 
the recruitment period.
Randomisation and masking
Participants were randomly assigned in a 1:1 ratio to 
receive either gabapentin or matched placebo through 
a secure online randomisation system, with the use 
of minimisation to balance trial group assignments 
according to presence or absence of dysmenorrhoea 
(pain score of ≥4 on a 0–10 NRS), psychological distress 
(General Health Questionnaire17 score ≥2), current use of 
hormonal contraceptives, and hospital centre. The 
appearance, route, and administration of the assigned 
intervention were identical in both groups. Patients, 
clinicians, and research staff were unaware of the trial 
group assignments throughout the trial. Participants 
were unmasked once they had provided all outcome data 
at week 16–17, or sooner if a serious adverse event 
requiring knowledge of the study drug occurred.
Procedures
Participants took the assigned drugs orally, every day 
from the time of randomisation to 16 weeks after 
randomisation. The study drugs were supplied by Sharp 
Clinical Services UK, who procured the gabapentin and 
manufactured the placebo capsule, over-encapsulated the 
gabapentin, and dispensed all capsules into numbered 
Gabapentin 
(n=153)
Placebo (n=153)
Dysmenorrhoea* 100 (65%) 100 (65%)
GHQ score for anxiety and 
depression†
38 (25%) 38 (25%)
GHQ total score† 4·6 (3·7) 4·7 (3·7)
Current use of sex hormones 99 (65%) 99 (65%)
Patch 2/99 (2%) 0
Combined oral contraceptive 
pill
26/99 (26%) 21/99 (21%)
Progesterone-only pill 19/99 (19%) 16/99 (16%)
Levonorgestrel-releasing 
intrauterine system
38/99 (38%) 45/99 (45%)
Implant 12/99 (12%) 12/99 (12%)
Injection 5/99 (5%) 8/99 (8%)
Age (years) 30·5 (7·7) 30·1 (8·6)
Ethnicity
White 150 (98%) 148 (97%)
Black (Caribbean, African, 
or other)
1 (1%) 0
Asian (Indian, Pakistani, 
Bangladeshi, or other)
2 (1%) 4 (2%)
Mixed (Caribbean, African, 
Asian, or other)
0 1 (1%)
Body-mass index (kg/m²) 27·1 (5·7), 151 27·8 (5·9), 150
Education
Primary 4 (3%) 5 (3%)
Secondary 47 (31%) 46 (30%)
Tertiary 101 (66%) 101 (66%)
Missing 1 (1%) 1 (1%)
Menstruating 109 (71%) 108 (71%)
Pain score during periods* 7·7 (1·6), 103 7·6 (1·7), 103
PUF symptom score‡ 9·7 (4·1) 10·0 (4·5), 148
PUF bother score‡ 5·3 (2·6) 5·4 (2·8), 150
PUF total score‡ 15·0 (6·3) 15·5 (7·0), 147
Rescue medications 114 (75%) 112 (73%)
Non-steroidal anti-
inflammatory drugs
62/114 (54%) 66/112 (59%)
Opiates 78/114 (68%) 68/112 (61%)
Other (includes paracetamol) 61/114 (54%) 58/112 (52%)
Neuropathic pain§ 32 (21%) 33 (22%)
Missing¶ 1 4
Data are n (%); mean (SD); mean (SD), N; or n/N (%) when N is different to the 
total number of participants. GHQ=General Health Questionnaire. PUF=Pelvic Pain 
and Urinary Frequency Patient Symptom Scale. *Dysmenorrhoea is defined as a 
pain score ≥4 during periods. Pain scores range from 0 to 10, where 0 is no pain 
and 10 is the worst pain imaginable. †GHQ scores range from 0 to 12, where higher 
scores represent higher amounts of mental distress. A score of 0 or 1 meets the 
definition of anxiety and depression. ‡PUF symptom score ranges from 0 to 23, 
PUF bother score ranges from 0 to 12, and PUF total score ranges from 0 to 35; 
a score greater than 12 is indicative of clinically significant symptoms. §Defined as 
a PainDETECT score ≥19. ¶Participants missing a neuropathic pain (PainDETECT) 
score.
Table 1: Demographic and baseline characteristics of participants
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containers. The dosing regimen included a 4-week 
titration phase where each participant started on one 
capsule (300 mg) daily, and increased the dose by one 
capsule every 3 days until they perceived that they were 
gaining adequate pain relief, or reported side-effects that 
precluded them from further increases, up to a maximum 
dose of nine capsules. If necessary, participants were 
advised to titrate down to the last tolerated dose with 
minimal side-effects. They were also asked to maintain 
their highest tolerated dose until the end of week 16. 
Study drugs were dispensed at time of randomisation, at 
weeks 4–5, and (dependent on the maximum tolerated 
dose reached) at weeks 8–10. Other analgesic medi-
cations, including opioids and antidepressants (but 
excluding those contraindicated alongside gabapentin) 
were allowed and their use was recorded.
Outcomes
The dual primary outcome measures of worst and 
average pain scores were recorded on a NRS at 
13–16 weeks after randomisation. They were collected via 
weekly text messages and assessed or interpreted as 
separate outcomes. The final worst pain score was taken 
as the worst response from the worst pain scores 
returned, and the average pain score as the mean of the 
average pain scores returned. Non-responders were 
contacted by telephone and the pain scores reported 
verbally. Second ary outcome measures comprised an 
examination at 16 weeks after randomisation of the 
proportion of women who had a 30% or 50% reduction 
in worst and average NRS pain scores (from baseline to 
end of treatment); global patient impression of change; 
general quality of life (Short Form-12),18 further pain 
assessment (Brief Pain Inventory),19 assessment for 
neuropathic-like features of pain (PainDETECT),20 
fatigue assessment (Brief Fatigue Inventory),21 psy-
chological distress (General Health Questionnaire),17 
pain-related cognitions (Pain Catastrophizing Scale),22 
impairments in paid work or activities (Work and 
Productivity Activity Impairment Questionnaire),23 and 
sexual functioning (Sexual Activity Questionnaire).24 
Patient-reported questionnaires were collected at weeks 
16–17 post-randomisation. The Pelvic Pain and Urinary 
Frequency Patient Symptom Scale was completed at 
baseline only. Data on use of analgesics, serious adverse 
events, and side-effects were collected at weeks 4–5 and 
8–10, either when the study drug was dispensed or by 
telephone. Women were asked to report appointments 
with health-care professionals (eg, general practitioner or 
hospital doctor). Reporting was restricted to appointments 
in relation to chronic pelvic pain, in addition to those 
required by the trial. We attempted to collect outcome 
data for all participants who were randomly assigned, 
regardless of adherence to the trial group assignment. 
Adherence to the study drug was collected using treat-
ment diaries which recorded the number of tablets taken 
daily, alongside self-reported estimates of adherence. 
Adherence to treatment was defined as taking more than 
50% of the study drug, self-reported at weeks 16–17.
Statistical analysis
The planned sample size of 240 women was estimated to 
provide 90% power to detect a minimally important 
clinical difference in NRS scores of one point on a 
0–10 scale, assuming a SD of 2·5. There is a body of 
literature10,25 to support one point on a NRS or 1 cm on a 
visual analogue scale representing minimal or little 
change, and 2·0–2·7 points being much or some change. 
To account for any increase in the risk of type 1 error that 
could be associated with having dual outcome measures, 
Baseline End of study Change from baseline Mean difference* (97·5% CI; 
p value)
Gabapentin (n=153) Placebo (n=153) Gabapentin (n=153) Placebo (n=153) Gabapentin Placebo
Worst NRS pain score 8·4 (1·3) 8·6 (1·2) 7·1 (2·6), 124 7·4 (2·2), 122 –1·4 (2·3), 124 –1·2 (2·1), 122 –0·20 (–0·81 to 0·42; p=0·47)
Average NRS pain score 5·5 (1·7) 5·5 (1·7) 4·3 (2·3), 123 4·5 (2·2), 121 –1·1 (2·0), 123 –0·9 (1·8), 121 –0·18 (–0·71 to 0·35; p=0·45)
Data are mean (SD) or mean (SD), N when N is different to the total number of participants, unless otherwise specified. NRS=numerical rating scale. *Adjusted for baseline score and minimisation variables. 
Values <0 favour gabapentin. Threshold for significance α=0·025 because of Bonferroni correction.
Table 2: Primary outcomes
Figure 2: Longitudinal plot of primary outcome measurements in each trial group
Error bars indicate the SE. NRS=numerical rating scale.
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a Bonferroni correction was applied (with a two-sided 
α-level of 0·025). We planned to include 300 women in 
the trial to account for up to 20% loss to follow-up.
The dual primary outcome measures are presented as 
means and SDs, alongside adjusted mean differences 
(with corresponding 97·5% CIs) produced from a linear 
regression model. Mean differences were adjusted for 
baseline score and minimisation variables. Mean change 
from baseline is also presented by group. The primary 
analysis is equivalent to a change from baseline analysis 
when also adjusting for baseline score. 97·5% CIs have 
been used and p values have been reported from two-
sided tests at the 2·5% significance level, to account for 
the Bonferroni correction applied to the dual primary 
outcome measures. NRS scores were further analysed 
using a repeated-measures model in which all assessment 
times were included. Binary secondary outcomes are 
presented as risk ratios produced from a log-binomial 
regression model. All continuous secondary outcome 
measures are presented as mean differences produced 
from a linear regression model. Appointments with 
health-care professionals for chronic pelvic pain and use 
of analgesics, in addition to appointments required by 
the trial, are reported descriptively only. All secondary 
outcomes are reported as point estimates with 99% CIs 
(without p values). All analyses, including assessment of 
safety and adverse events, were done by intention to 
treat and adjusted for the presence of dysmenorrhoea, 
psychological distress defined by the General Health 
Questionnaire,17 current use of hormonal contraceptive, 
recruiting hospital, and baseline score. Sensitivity ana-
lyses for the dual primary outcomes include a per-
protocol analysis, an assess ment of missing primary 
outcome data by means of a multiple-imputation 
Baseline End of study Estimate (99% CI)
Gabapentin (n=153) Placebo (n=153) Gabapentin (n=153) Placebo (n=153)
Reduction in NRS score from baseline (≥30%)
Worst NRS pain score ·· ·· 30/124 (24%) 21/122 (17%) 1·38 (0·72 to 2·64)*
Average NRS pain score ·· ·· 44/123 (36%) 37/121 (31%) 1·12 (0·70 to 1·80)*
Reduction in NRS score from baseline (≥50%)
Worst NRS pain score ·· ·· 19/124 (15%) 10/122 (8%) 1·84 (0·71 to 4·75)*
Average NRS pain score ·· ·· 27/123 (22%) 19/121 (16%) 1·36 (0·68 to 2·72)*
Patient global impression of change
Very marked or marked improvement ·· ·· 34/112 (30%) 22/108 (20%) 1·48 (0·80 to 2·73)†
Minimal improvement or worsening‡ ·· ·· 78/112 (70%) 86/112 (80%) ··
Patient-reported questionnaires
Short Form-12 mental component score 40·3 (10·8) 39·5 (11·3), 149 41·3 (10·6), 111 42·5 (11·1), 110 –1·11 (–4·60 to 2·39)§
Short Form-12 physical component score 39·0 (9·2) 40·1 (9·4), 149 43·8 (10·6), 111 44·6 (10·1), 110 0·49 (–2·27 to 3·24)§
Brief Pain Inventory pain interference score 4·9 (2·6), 152 5·0 (2·6), 152 3·6 (2·8), 111 3·6 (2·8), 112 –0·04 (-0·84 to 0·77)¶
Brief Fatigue Inventory global fatigue score 5·3 (2·4) 5·1 (2·3), 152 4·2 (2·5), 111 4·0 (2·7), 112 0·12 (-0·65 to 0·89)¶
General Health Questionnaire total score 4·6 (3·7) 4·7 (3·7) 3·8 (3·9), 111 3·0 (3·5), 111 0·72 (–0·49 to 1·94)¶
WPAIQ activity impairment score 53·4 (25·1) 52·1 (25·4), 151 39·3 (29·0), 110 38·6 (29·6), 111 –0·77 (–9·66 to 8·12)¶
WPAIQ absenteeism score|| 10·9 (23·2), 117 12·0 (25·6), 121 10·8 (23·5), 83 4·9 (15·1), 89 5·32 (–2·06 to 12·71)¶
WPAIQ presenteeism score** 47·1 (26·2), 109 46·5 (26·7), 104 36·4 (28·4), 72 38·0 (29·6), 79 –1·89 (–14·43 to 10·65)¶
WPAIQ work productivity loss score** 49·7 (27·9), 109 49·2 (28·2), 103 39·9 (31·1), 72 39·2 (30·7), 79 –0·43 (–13·73 to 12·87)¶
Pain Catastrophising Questionnaire total 
score
27·4 (12·9) 27·2 (13·0), 152 20·8 (14·6), 111 19·7 (12·5), 111 0·48 (–3·24 to 4·20)¶
SAQ pleasure score†† 10·2 (4·1), 117 9·7 (4·8), 101 10·8 (4·5), 83 10·9 (4·1), 69 –0·14 (–1·84 to 1·56)§
SAQ discomfort score†† 2·9 (1·6), 117 3·1 (1·8), 100 3·6 (1·9), 84 3·3 (2·0), 68 0·17 (–0·55 to 0·90)§
SAQ habit score†† 0·8 (0·6), 118 0·6 (0·6), 101 1·1 (0·8), 83 0·9 (0·7), 69 0·19 (–0·15 to 0·53)§
PainDETECT total score 13·6 (6·9), 152 13·3 (6·5), 149 12·4 (6·8), 111 10·9 (6·7), 107 1·19 (–0·74 to 3·12)¶
Data are n/N (%); mean (SD); or mean (SD), N, when N is different to the total number of participants, unless otherwise specified. Patient-reported questionnaires were 
collected at weeks 16–17 post-randomisation. Worst and average NRS, Brief Pain Inventory, and Brief Fatigue Inventory scores range from 0 to 10, Short-Form 12 and WPAIQ 
scores range from 0 to 100, General Health Questionnaire scores range from 0 to 12, Pain Catastrophising Questionnaire scores range from 0 to 52, SAQ pleasure scores range 
from 0 to 18, SAQ discomfort scores range from 0 to 6, SAQ habit scores range from 0 to 3, and PainDETECT scores range from –1 to 38. NRS=numerical rating scale. 
WPAIQ=Work Productivity and Activity Impairment Questionnaire. SAQ=Sexual Activity Questionnaire. *Risk ratio (99% CI), adjusted for baseline score and minimisation 
variables. Values >1 favour gabapentin. †Risk ratio (99% CI), adjusted for minimisation variables. ‡Includes minimal improvement, no change, minimal worsening, marked 
worsening and very marked worsening. Values >1 favour gabapentin. §Mean difference (99% CI), adjusted for baseline score and minimisation variables. Values >0 favour 
gabapentin. ¶Mean difference (99% CI), adjusted for baseline score and minimisation variables. Values <0 favour gabapentin. ||In women who are currently employed. 
**In women who are currently employed and working >0 hours in the past 7 days. ††In women who are currently sexually active (baseline: gabapentin=123, placebo=105; 
week 16: gabapentin=87, placebo=74); the table reports only data for those who are sexually active who returned data.
Table 3: Secondary outcomes
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approach, and an analysis to assess the effect of time 
between screening and randomisation.
Three prespecified subgroup analyses were done on 
the basis of presence or absence of dysmenorrhoea, 
psychological distress defined by the General Health 
Questionnaire17 (score 0–1 or 2–12), and current use of 
hormonal contraceptives (yes or no). These subgroup 
analyses were limited to the dual primary outcomes 
only. The treatment effect within these subgroups was 
examined by the measurement of treatment-by-subgroup 
interaction in the linear regression model.
Interim analyses of effectiveness and safety endpoints 
were done by the trial statistician (who remained 
unaware of treatment assignments) on behalf of the data 
and safety monitoring committee at approximately 
12-month inter vals during the recruitment period. 
Because the interim analyses were done according to the 
Haybittle–Peto principle,26 no adjustment was made in 
the final p values to measure significance. All analyses 
were done in SAS (version 9.4). This trial is registered 
with the ISRCTN registry, ISCRTN77451762.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, writing of 
the report, or decision to submit the results for pub-
lication. The corresponding author and trial statisticians 
had full access to all the data in the study. All authors in 
the writing team shared final responsibility for the 
decision to submit for publication. The manu facturers 
of the gabapentin drug used for this trial and Sharp 
Clinical Services UK were not involved in any aspect of 
the study.
Results
Participants were screened between Nov 30, 2015, and 
March 6, 2019. Of the 1348 women who were approached 
for participation, 414 were initially considered eligible 
based on clinical criteria (figure 1). Of these 414 women, 
306 were randomly assigned (153 to gabapentin and 
153 to placebo). 80% of partic ipants had available data 
for the dual primary outcome measures (246 [80%] worst 
scores returned; 244 [80%] average scores returned). 
The groups were well balanced for all characteristics 
measured at baseline (table 1).
There were no significant between-group differences 
in both worst and average NRS pain scores at 13–16 weeks 
after randomisation. The mean worst NRS pain score 
was 7·1 (SD 2·6) in the gabapentin group and 7·4 
(SD 2·2) in the placebo group. Mean change from 
baseline was –1·4 (SD 2·3) in the gabapentin group and 
–1·2 (SD 2·1) in the placebo group (adjusted mean 
difference –0·20 [97·5% CI –0·81 to 0·42]; p=0·47). The 
mean average NRS pain score was 4·3 (SD 2·3) in the 
gabapentin group and 4·5 (SD 2·2) in the placebo group. 
Mean change from baseline was –1·1 (SD 2·0) in the 
gabapentin group and –0·9 (SD 1·8) in the placebo group 
(adjusted mean difference –0·18 [97·5% CI –0·71 to 0·35]; 
p=0·45; table 2; figure 2).
Point estimates and CIs from the prespecified sensitivity 
analyses and further analyses from the repeated-mea-
sures model were consistent with the primary analysis 
(appendix pp 2–3). There was no evidence of varying effect 
in the three prespecified subgroup analyses (appendix p 4).
No significant differences were noted in the proportion 
of women who had a reduction in NRS scores from 
baseline or any other patient-reported secondary outcomes 
(table 3). Women in the gabapentin group reported they 
were taking fewer painkillers, but these differences were 
not significant (appendix p 5).
A higher proportion of women had a serious adverse 
event in the gabapentin group (10 [7%] of 153) than in 
the placebo group (3 [2%] of 153; p=0·04; table 4). 
One participant who was on gabapentin died of a 
complication of pneumonia which was exacerbated by 
other comorbidities, but this was not considered related 
to study participation. Known side-effects (as reported in 
the summary of product characteristics) of dizziness, 
drowsiness, and visual disturbances were more common 
in the gabapentin group than in the placebo group 
(table 4), but did not appear to prompt greater use of 
health-care resources (appendix p 7).
Adherence to the study drug was similar between both 
the gabapentin and placebo groups (101 [90%] in the 
gabapentin group compared with 101 [93%] in the 
placebo group). A detailed breakdown of the extent of 
self-reported adherence to the study drug is shown in the 
appendix (p 8). The overall median dose taken daily per 
week was calculated for each group and is presented in 
the appendix (p 9). The doses used during the escalation 
phase were equal between the groups, thereafter the 
participants in the gabapentin group generally took one 
capsule (300 mg) more than those in the placebo group 
throughout the treatment period. At week 4, the median 
See Online for appendix
Gabapentin (n=153) Placebo (n=153) Risk ratio* (99% CI) p value
Side-effects
Dizzy 66/122 (54%) 32/114 (28%) 1·91 (1·22–2·99) 0·0002
Tired 85/129 (66%) 68/120 (57%) 1·12 (0·86–1·44) 0·3
Drowsy 64/124 (52%) 34/116 (29%) 1·71 (1·09–2·68) 0·002
Change in mood 55/118 (47%) 43/112 (38%) 1·17 (0·79–1·74) 0·3
Change in urinary pattern 37/114 (32%) 35/111 (32%) 1·00 (0·61–1·63) 1·0
Visual disturbances 25/113 (22%) 12/110 (11%) 2·25 (0·99–5·10) 0·01
Change in skin 31/112 (28%) 23/110 (21%) 1·35 (0·74–2·50) 0·2
Different pain 33/116 (28%) 37/117 (32%) 0·88 (0·53–1·46) 0·5
Shortness of breath 17/114 (15%) 11/109 (10%) 1·45 (0·57–3·71) 0·3
Adverse events
Serious adverse event 10/153 (7%) 3/153 (2%) ·· 0·04
Data are n/N (%), unless otherwise specified. The total number of serious adverse events was 15 (12 in the gabapentin 
group, and three in the placebo group). *Adjusted for baseline score and minimisation variables. Values <1 favour 
gabapentin.
Table 4: Summary of reported side-effects and adverse events
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maximum tolerated number of tablets was equivalent to 
2100 mg in both groups, although this reached 2700 mg 
(maximum permitted dose) in future weeks for some 
women.
Discussion
This multicentre, randomised, double-blind, placebo-
controlled trial showed that, in women with chronic pelvic 
pain and no obvious pelvic pathology, gabapentin was no 
more effective than placebo in reducing pain. The trial 
was powered adequately to detect differences between 
trial groups, and the between-group point estimates 
and corresponding CIs excluded a minimally important 
clinical difference of one point on a 0–10 pain scale, so we 
can confidently conclude that gabapentin is not effective 
for chronic pelvic pain at a group level. The incidence of 
side-effects and serious adverse events was higher in the 
gabapentin group than in the placebo group. We do not 
believe that the inclusion of a small proportion of women 
with neuropathic-like pain (65 [22%] of 301 participants) 
and potentially a number of actual neuropathies, explains 
the lack of efficacy of gabapentin over placebo overall in 
our study, given that there was no difference in mean 
PainDETECT scores between the two groups at baseline 
nor at the end of the study.
We used a dual primary outcome measure and 
considered both worst and average pain scores. These 
outcomes were considered separately and an improve-
ment in one (or both) would conclude gabapentin was 
efficacious. Although we acknowledge that it is preferable 
to have a single primary outcome, a survey of our patient 
involvement group found that worst and average pain were 
equally important to women.26 We therefore collected the 
pain scores weekly over a 4-week period, asking participants 
to rate both worst and average pain for the preceding week, 
and defined a minimum number of responses to create 
a valid outcome. We used this approach because chronic 
pelvic pain can fluctuate during a woman’s menstrual 
cycle, so eliciting a pain score at a single timepoint is 
unlikely to capture the effect of gabapentin nor reflect the 
woman’s experience of pain. All outcome data in the trial 
were subjective or participant-reported outcomes (rather 
than laboratory measurements), but the study was blinded, 
reducing risk of incurring assessor bias.
The calculation for the sample size for the trial was 
based on a recognised minimally important clinical 
difference for chronic pain25 of one point on a 0–10 NRS, 
and used a SD from a comparable pilot study.10 Appro-
priate adjustments were applied to account for the dual 
primary outcome in both the sample size calculation and 
analysis. The target number of women were recruited 
and missing outcome data were as anticipated, with a 
follow-up rate for the dual primary outcome of 80% of 
women (246 [80%] worst NRS and 244 [80%] average 
NRS). The sensitivity analysis was almost identical to the 
observed data comparison and the CIs for both did not 
reach the minimally important clinical difference, so it is 
unlikely a meaningful treatment effect was missed 
because of missing data.
Rate of adherence to the trial regimen was high (women 
reported taking at least half of the study drug doses 
throughout the trial), but was not validated against an 
objective method such as pill-counting. The dose of 
gabapentin that participants received was based on 
individual adjustment of the dose by the participants 
themselves, which reflected their perception of pain relief 
and side-effects. Adjustments were made in accordance 
with existing dosing recommendations,27 up to a dose 
of 2700 mg per day, and final doses ranged from 600 mg 
to 2700 mg per day during the treatment phase. When the 
trial protocol was written, 2700 mg was the maximum 
dose recommended by the British National Formulary, 
and only pain clinics used to prescribe above this dose. We 
recognise that it is now generally accepted that higher 
doses can be prescribed, if side-effects permit.
We also acknowledge that it would have been interesting 
to look at the effect of review by a pain specialist or 
specialist pain medicine prescription on outcomes, but we 
did not document whether patients had been seen by a 
pain specialist at the outset of the trial. However, it is 
worth noting that within the UK, pain management 
approaches for chronic pelvic pain are not usually 
considered until after all gynaecological and other relevant 
specialist (eg, urology, gastroenterology) assess ments and 
appropriate treatments are complete, or not providing 
symptom improvement. Therefore, it is unlikely that the 
women enrolled in this trial would have been seen by a 
pain specialist with regards to their pelvic pain.
Although more women in the placebo group were able 
to correctly guess their allocation at the end of the 
treatment period (78 [74%] of 106 correctly guessed 
placebo and 64 [58%] of 111 correctly guessed gabapentin), 
their use of rescue medication was similar. We cannot 
conclude that women who perceived they were taking 
placebo compensated by increasing their analgesic use 
and thus negated any effect of gabapentin.
The higher rates of side-effects observed with gabapentin 
compared with placebo (eg, dizziness, drowsiness, and 
visual disturbances) in the trial are consistent with other 
published studies. A 2018 meta-analysis of all trials for 
postherpetic neuralgia and painful diabetic neuropathy28 
showed that, compared with placebo, gabapentin was 
associated with more drowsiness (gabapentin 14% vs 
placebo 5%; p<0·001) and dizziness (gabapentin 19% vs 
placebo 7%; p<0·001). Nevertheless, the rates of side-
effects in our trial are lower than in these other studies, 
despite only measuring these in women. This would 
suggest that women are not more susceptible to 
developing side-effects from gabapentin than men.
Similar to many clinical trials for treatments for pain, 
we observed a potential placebo effect.29 The trial was not 
designed to investigate the neurobiological mechanisms 
behind this effect, but information offered in relation to 
treatment, patients’ expectations, previous encounters 
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with gabapentin, and the therapeutic milieu can all 
generate this response.30 Nonetheless, the placebo effect 
observed is very relevant, because of the side-effect profile 
of gabapentin and its potential addictive prop erties.31
In conclusion, our results show that gabapentin did not 
relieve pain in women with chronic pelvic pain, and that 
gabapentin was associated with higher rates of side-
effects than placebo.
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